Web of Science: 12 cites, Scopus: 10 cites, Google Scholar: cites,
The impact of onabotulinumtoxinA on severe headache days : PREEMPT 56-week pooled analysis
Matharu, Manjit (Queen Square, London, WC1N3BG UK)
Halker, Rashmi (East Mayo Blvd, Phoenix, AZ 85054 USA)
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
DeGryse, Ronald (Allergan plc, 2525 Dupont Dr, Irvine, CA USA)
Manack Adams, Aubrey (Allergan plc, 2525 Dupont Dr, Irvine, CA USA)
Aurora, Sheena K. (Pasteur Dr. Room A301 MC 5325, Stanford, CA USA)
Universitat Autònoma de Barcelona

Data: 2017
Resum: OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day severity in patients with CM among those patients who were deemed non-responders based on reduction in the frequency of headache days alone. Data from the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical trial program (a 24-week, 2-treatment cycle, double-blind, randomized, placebo-controlled, parallel-group phase, followed by a 32-week, 3-treatment cycle, open-label phase) were pooled for analysis. Patients kept a daily diary to record headache severity on a 4-point scale (from none to severe), and a 6-domain Headache Impact Test (HIT-6) was used to determine the clinical impact of headaches. Analysis was undertaken to assess whether the subset of patients that were headache-day frequency non-responders at week 24 (patients with <50% reduction in headache-day frequency) experienced a reduction in headache severity whilst receiving onabotulinumtoxinA. For headache-day frequency non-responders, significant reductions in the number of severe headache days, average daily headache severity, pooled percentage of severe headache days and headache severity score were observed at week 24 for patients who had received onabotulinumtoxinA compared with those who had received placebo. The between-group differences were reduced and non-significant at week 56. Similarly, headache-day frequency non-responders receiving onabotulinumtoxinA were found to have an improvement in the clinical impact of headaches using results from the HIT-6. These results suggest that even those patients with CM who are deemed non-responders based on analysis of headache frequency alone experience clinically meaningful relief from headache intensity following treatment with onabotulinumtoxinA. The online version of this article (doi:10. 1186/s10194-017-0784-4) contains supplementary material, which is available to authorized users.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: article ; recerca ; publishedVersion
Matèria: Chronic migraine ; OnabotulinumtoxinA ; Headache severity ; Hit-6 ; PREEMPT
Publicat a: Journal of headache and pain, Vol. 18 (august 2017) , ISSN 1129-2377

DOI: 10.1186/s10194-017-0784-4
PMID: 28766236

8 p, 843.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-02-08, darrera modificació el 2020-09-10

   Favorit i Compartir